Swiss drug giant Roche pays €380m for Irish biotech Inflazome
21 September 2020
A startup company developing treatments for inflammatory diseases based on a research partnership between the University of Queensland and Trinity College Dublin has been acquired in a landmark deal, one of the largest in Australian and Irish biotech history. Inflazome has been acquired by Roche for an upfront cash payment of €380 million, plus additional payments based on the achievement of certain milestones. Headquartered in Dublin, the company is developing drugs to address clinical unmet needs in inflammatory diseases by targeting inflammasomes, which are understood to drive many chronic inflammatory conditions.
Luke said: ‘I am delighted to have Roche as our partner. They will run multiple clinical trials in a number of inflammatory diseases with our molecules. This story began in the School of Biochemistry and Immunology and a big thanks to all who helped us along the way!’